AR030019A1 - HUMAN MONOCLONAL ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THE SAME, A PROCEDURE FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A NUCLEIC ACID ISOLATED MOLECULA, A RECOMBINANT PLASMIDE, A HOSPED DIFFERENT USE OF A MUSCLE - Google Patents
HUMAN MONOCLONAL ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THE SAME, A PROCEDURE FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A NUCLEIC ACID ISOLATED MOLECULA, A RECOMBINANT PLASMIDE, A HOSPED DIFFERENT USE OF A MUSCLEInfo
- Publication number
- AR030019A1 AR030019A1 ARP000102352A ARP000102352A AR030019A1 AR 030019 A1 AR030019 A1 AR 030019A1 AR P000102352 A ARP000102352 A AR P000102352A AR P000102352 A ARP000102352 A AR P000102352A AR 030019 A1 AR030019 A1 AR 030019A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibodies
- human monoclonal
- nucleic acid
- pharmaceutical compositions
- production
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se refiere a nuevos anticuerpos monoclonales humanos (los mAb) y a los genes que codifican los mismos. Más específicamente, se refiere a anticuerpos monoclonales humanos específicamente reactivos con un epítope de la proteína de fusion (F) del virus sincitial respiratorio (RSV). Tales anticuerpos son utiles para el tratamiento terapéutico y/o profiláctico de la infeccion por RSV en pacientes humanos particularmente lactantes y ninos pequenos. Se describe además a un procedimiento para su produccion, composiciones farmacéuticas que los comprenden, una molécula de ácido nucleico aislada, un plásmido recombinante, una célula hospedante y el uso de dichos anticuerpos para la manufactura de un medicamento y para un agente de diagnostico.It refers to new human monoclonal antibodies (mAbs) and the genes encoding them. More specifically, it refers to human monoclonal antibodies specifically reactive with an epitope of the respiratory syncytial virus (RSV) fusion protein (F). Such antibodies are useful for the therapeutic and / or prophylactic treatment of RSV infection in particularly lactating human patients and young children. A method for its production is further described, pharmaceutical compositions comprising them, an isolated nucleic acid molecule, a recombinant plasmid, a host cell and the use of said antibodies for the manufacture of a medicament and for a diagnostic agent.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13470299P | 1999-05-18 | 1999-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030019A1 true AR030019A1 (en) | 2003-08-13 |
Family
ID=22464579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102352A AR030019A1 (en) | 1999-05-18 | 2000-05-16 | HUMAN MONOCLONAL ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THE SAME, A PROCEDURE FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A NUCLEIC ACID ISOLATED MOLECULA, A RECOMBINANT PLASMIDE, A HOSPED DIFFERENT USE OF A MUSCLE |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1178829A4 (en) |
| JP (1) | JP2002543822A (en) |
| AR (1) | AR030019A1 (en) |
| AU (1) | AU5441000A (en) |
| CO (1) | CO5280147A1 (en) |
| WO (1) | WO2000069462A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4794301B2 (en) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | Antibody production method |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
| ES2592271T3 (en) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide production methods by regulating the association of polypeptides |
| JP5085322B2 (en) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | Pharmaceutical composition containing sc (Fv) 2 |
| CA2611726C (en) * | 2005-06-10 | 2017-07-11 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(fv)2 |
| AU2006256041B2 (en) | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| CN105177091A (en) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP3424526A1 (en) | 2008-06-05 | 2019-01-09 | Ablynx NV | Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies |
| LT2438087T (en) | 2009-06-05 | 2017-08-25 | Ablynx N.V. | Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
| SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
| JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5762905A (en) * | 1992-09-16 | 1998-06-09 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| CA2270288A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
-
2000
- 2000-05-16 AR ARP000102352A patent/AR030019A1/en not_active Application Discontinuation
- 2000-05-16 CO CO00035406A patent/CO5280147A1/en not_active Application Discontinuation
- 2000-05-18 WO PCT/US2000/013694 patent/WO2000069462A1/en not_active Application Discontinuation
- 2000-05-18 AU AU54410/00A patent/AU5441000A/en not_active Abandoned
- 2000-05-18 EP EP00939304A patent/EP1178829A4/en not_active Withdrawn
- 2000-05-18 JP JP2000617922A patent/JP2002543822A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1178829A4 (en) | 2005-06-08 |
| AU5441000A (en) | 2000-12-05 |
| EP1178829A1 (en) | 2002-02-13 |
| CO5280147A1 (en) | 2003-05-30 |
| WO2000069462A1 (en) | 2000-11-23 |
| JP2002543822A (en) | 2002-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030019A1 (en) | HUMAN MONOCLONAL ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THE SAME, A PROCEDURE FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A NUCLEIC ACID ISOLATED MOLECULA, A RECOMBINANT PLASMIDE, A HOSPED DIFFERENT USE OF A MUSCLE | |
| DE69609188D1 (en) | NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS | |
| JP2002544238A5 (en) | ||
| CN105566497A (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| ATE267258T1 (en) | VACCINES FOR THE RESPIRATORY SYNZYTIAL VIRUS WITH NUCLIC ACIDS | |
| CA2181832A1 (en) | Immunization by inoculation of dna transcription unit | |
| WO2002072636A3 (en) | Crystals of whole antibodies and fragments thereof and methods for making and using them | |
| YU36302A (en) | Novel tiotropium preparation -containing inhalation powder | |
| BR9907691A (en) | Derivatives of antigen associated with tumor of the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and compositions for vaccination | |
| JP2011521662A5 (en) | ||
| JP2004501618A5 (en) | ||
| JP2009520758A5 (en) | ||
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| AR035867A1 (en) | A PARTICLE SIMILAR TO A HCV VIRUS FORMED BY A HCV WRAPPING PROTEIN, A METHOD FOR FORMING THE PARTICULATE, A MEDICINAL PRODUCT CONTAINING IT, A VACCINE, A DETECTION METHOD, A DIAGNOSTIC KIT, USE OF CEPAS OF HANS FOR THE EXPRESSION OF A HCV PROTEIN, E | |
| CN111440229A (en) | Novel coronavirus T cell epitope and application thereof | |
| CN105106945B (en) | A kind of helicobacter pylori tetravalence virulence factor polyepitope vaccines and preparation method thereof | |
| JPH02109994A (en) | Monoclonal antibody and in-vitro and in-vivo neutralization of toxity of tnf-alpha by fregment induced from said antibody | |
| CN113769080B (en) | Polypeptide immunoconjugates and uses thereof | |
| CN107849551A (en) | New trypsase is the same as work(iso series and its purposes | |
| JPH05508847A (en) | Transfer factors and usage | |
| HUP0401605A2 (en) | Integrin inhibitors for the treatment of eye diseases | |
| WO2009079220A3 (en) | Recombinant elastase proteins and methods of manufacturing and use thereof | |
| WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| ES2108693T3 (en) | COMPOUNDS AND TREATMENTS FOR PNEUMONIA IN ANIMALS. | |
| CN111153988B (en) | Broad-spectrum neutralizing monoclonal antibody against enterovirus D68 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |